Telix Pharmaceuticals (TLX)

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Dagens Telix Pharmaceuticals Limited American Depositary Shares (TLX) aktiekurs på pre-market är , vilket speglar en NaN % pre-market rörelse sedan marknaden stängde. Företagets marknadsvärde är 2,39 md $, med en daglig handelsvolym på  aktier. Det tidigare stängningspriset var .

Redo att börja? Följ stegen nedan, eller läs vår guide om hur man köper Telix Pharmaceuticals aktier på Kraken med start från 10 $.